DRG Market Assessment reports

The treatment of ovarian cancer has historically been dominated by chemotherapy, but angiogenesis and PARP inhibitors are optimizing treatment options. The regulatory approvals of AstraZeneca /…

The treatment landscape for COVID-19 continues to evolve rapidly. Despite the availability of vaccines in the markets under study, ongoing research focuses on decreasing viral loads and improving…

According to Clarivate Epidemiology, there are approximately 4 million prevalent cases of Alzheimer’s disease (AD) and nearly 2.5 million prevalent cases of mild cognitive impairment (MCI) due to…

Clarivate Epidemiology’s coverage of Pompe disease comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany,…

A handful of newer disease-modifying therapies (DMTs) for multiple sclerosis (MS)—Novartis’s Mayzent, Bristol Myers Squibb’s Zeposia, Novartis’s Kesimpta, and Janssen’s Ponvory—have…

The treatment landscape for atopic dermatitis (AD) in the United States is undergoing a revolution. Since 2017, six new agents have been approved by the FDA (four of them since the start of 2021),…

Dyslipidemia is a key modifiable risk factor for cardiovascular (CV) disease. Current lipid-modifying therapies, including statins, ezetimibe, fibrates, omega-3 fatty acid compounds, and PCSK9…

Clarivate Epidemiology’s coverage of metachromatic leukodystrophy (MLD) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United…

Scleroderma, also known as systemic sclerosis (SSc), is characterized by progressive vasculopathy, progressive fibrosis, and autoimmunity. While disease severity and symptoms are heterogeneous, in…

The human immunodeficiency virus (HIV) therapy market is dynamic and growing. With the launches of many effective antiretroviral therapies (ART), such as Gilead’s Biktarvy and ViiV’s Dovato,…

Metastatic non-small-cell lung cancer (NSCLC) is a highly segmented indication defined by tumor histology and mutational status. Metastatic nonsquamous NSCLC patients are routinely tested for the…

Metastatic non-small-cell lung cancer (NSCLC) is a highly segmented indication defined by tumor histology and mutational status. Metastatic nonsquamous NSCLC patients are routinely tested for the…